Literature DB >> 6977633

HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients.

J C Jacobs, W E Berdon, A D Johnston.   

Abstract

HLA-B27 typing of all arthritic children helped to identify and focus attention on a subset whose disease was pathogenetically related to and demonstrated clinical features of ankylosing spondylitis and Reiter syndrome, but only rarely fulfilled current diagnostic criteria for those disorders (spondyloarthritis). In contrast to other forms of childhood arthritis, enthesopathy (inflammation at the sites of attachment of ligaments and tendons to bone) was a prominent feature in 75%; a family history of similar arthritis was obtained from 60%; boys were more frequently affected (2:1); urethritis, acute iritis, conjunctivitis, or keratoderma blennorrhagicum occurred at some time in 42%; and the initial attack followed an unexplained febrile illness, known dysentery or urethritis, or severe musculoskeletal trauma in 41%. The arthritis was generally pauciarticular, asymmetric, and primarily in the feet and large joints of the lower extremities. Distinctive radiographic features included periostitis, severe osteopenia, calcaneal erosions, and heel spurs; three of 58 had rapid destruction of a single joint. Only ten patients (all boys) were found to have radiographic sacroiliitis after an average of five years of disease, and only three had the Reiter triad. The lifetime risk of sacroiliitis and spinal ankylosis can only be determined by long-term follow-up of such prospectively identified groups of spondyloarthritic children.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6977633     DOI: 10.1016/s0022-3476(82)80746-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  25 in total

1.  Trauma and seronegative spondyloarthropathy.

Authors:  I Olivieri; G Gemignani; G Pasero
Journal:  Ann Rheum Dis       Date:  1990-05       Impact factor: 19.103

Review 2.  Classification of juvenile spondyloarthritis: Enthesitis-related arthritis and beyond.

Authors:  Robert A Colbert
Journal:  Nat Rev Rheumatol       Date:  2010-07-06       Impact factor: 20.543

Review 3.  Clinical observations programme in SpA: disease parameters, treatment options and practical management issues.

Authors:  Dirk Elewaut; Filip Van den Bosch; Gust Verbruggen; Filip de Keyser; Bert Vander Cruyssen; Herman Mielants
Journal:  Rheumatol Int       Date:  2008-09-26       Impact factor: 2.631

4.  Radiologic Findings in Children with Seronegative Spondyloarthropathies: Distinguishing the chronic arthropathies of childhood.

Authors:  E M Azouz; R Y Lévesque
Journal:  Can Fam Physician       Date:  1992-08       Impact factor: 3.275

5.  HLA B27 typing in 511 children with juvenile idiopathic arthritis from India.

Authors:  Rajni Srivastava; Sanat Phatak; Akhilesh Yadav; Preeti Bajpai; Amita Aggarwal
Journal:  Rheumatol Int       Date:  2016-07-13       Impact factor: 2.631

6.  Trauma and seronegative spondyloarthropathy: report of two more cases of peripheral arthritis precipitated by physical injury.

Authors:  I Olivieri; G Gemignani; C Christou; G Pasero
Journal:  Ann Rheum Dis       Date:  1989-06       Impact factor: 19.103

7.  Spondyloarthritis in a pediatric population: risk factors for sacroiliitis.

Authors:  Matthew L Stoll; Rafia Bhore; Molly Dempsey-Robertson; Marilynn Punaro
Journal:  J Rheumatol       Date:  2010-08-03       Impact factor: 4.666

8.  Idiopathic peripheral enthesopathy without spondylarthritis.

Authors:  M Nishikai; M Sugimoto; A Sato; H Takeuchi
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

Review 9.  Atypical spondyloarthritis in children: proposed diagnostic criteria.

Authors:  A Hussein; H Abdul-Khaliq; H von der Hardt
Journal:  Eur J Pediatr       Date:  1989-04       Impact factor: 3.183

10.  Sulphasalazine in the treatment of children with chronic arthritis.

Authors:  J L Huang; L C Chen
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.